Bicara Therapeutics Elects New Directors at Annual Meeting

The latest announcement is out from Bicara Therapeutics Inc. ( (BCAX) ).

On June 9, 2025, Bicara Therapeutics Inc. held its annual meeting of stockholders where two key proposals were considered. The stockholders elected Kiran Mazumdar-Shaw, Jake Simson, Ph.D., and Ryan Cohlhepp, Pharm D., as class I directors for a three-year term. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (BCAX) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Bicara Therapeutics Inc. stock, see the BCAX Stock Forecast page.

Spark’s Take on BCAX Stock

According to Spark, TipRanks’ AI Analyst, BCAX is a Neutral.

Bicara Therapeutics’ stock score reflects its high-risk profile typical of early-stage biotechnology companies. The primary concern is the lack of revenue and dependence on external funding, but a strong cash position provides some financial stability. The technical analysis shows positive momentum, though investors should be cautious of potential overbought conditions. Traditional valuation metrics are not applicable, emphasizing the importance of monitoring R&D progress and market sentiment.

To see Spark’s full report on BCAX stock, click here.

More about Bicara Therapeutics Inc.

Average Trading Volume: 826,437

Technical Sentiment Signal: Strong Sell

Current Market Cap: $686.1M

For an in-depth examination of BCAX stock, go to TipRanks’ Overview page.